Research > Focus A > Work Packages A03
Summary
Patient tumor tissues from N²M², a trial using molecular defined treatments first-line with radiotherapy alone, are analyzed with single nuclei (sn) RNA sequencing next to comprehensive molecular analysis to understand resistance pathways and subclonal evolution under targeted therapies. Putative resistance pathways will be studied in vitro and in vivo. With a specific focus in understanding the role of senescent tumor cells promoting this targeted therapy resistance. In addition, molecular, metabolic and imaging biomarkers from two retrospective as well as one prospective study will be analyzed.